A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Part of paid clinical trials in Lancaster, California.

Sponsor
Novo Nordisk A/S
Study ID
NCT07415954
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • NNC0662-0419 — DRUG
    NNC0662-0419 will be administered subcutaneously.
  • Semaglutide — DRUG
    Semaglutide will be administered subcutaneously.
  • Placebo — DRUG
    Placebo will be administered subcutaneously.

Study Details

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Key Dates

Start date
Apr 17, 2026
Status verified
May 2026
Primary completion
Sep 3, 2027
Completion
Oct 1, 2027

Study Design

Enrollment
270 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0662-0419
    Participants will receive NNC0662-0419 subcutaneously (s.c.) in a dose escalating manner once weekly.
  • Active Comparator: Semaglutide
    Participants will receive semaglutide s.c. once weekly.
  • Placebo Comparator: Placebo
    Participants will receive placebo matched to their respective investigational medicinal product s.c. once weekly.

Primary Outcome Measure

Change in glycated haemoglobin (HbA1c) (week 16) [ Time Frame: From baseline (week 0) to week 16 ]

Central Contacts

Locations (23)

FacilityCityStateZIPSite coordinators
First Valley Medical GroupLancasterCalifornia93534-
Torrance Clinical Research Institute, Inc.LomitaCalifornia90717-
Ark Clinical ResearchLong BeachCalifornia90815-
Pacific Clinical StudiesLos AlamitosCalifornia90720-
Wetlin Research Associates, Inc.San DiegoCalifornia92120-
Diablo Clinical Research, Inc.Walnut CreekCalifornia94598-
Encore Medical Research LLCHollywoodFlorida33024-
Bioclinical Research AllianceMiamiFlorida33155-
South Broward Research LLCMiramarFlorida33027-
West Orange EndocrinologyOcoeeFlorida34761-
Encore Medical Research of WestonWestonFlorida33331-
Elite Clinical TrialsBlackfootIdaho83221-
Cedar-Crosse Research CenterChicagoIllinois60607-
Brigham & Women's HospitalBostonMassachusetts02115-5804-
Headlands ResearchSpringfieldMissouri65807-
PharmQuestGreensboroNorth Carolina27408-
Piedmont Healthcare StatesvilleStatesvilleNorth Carolina28625-
Providence Center for Clinical ResearchDaytonOhio45439-
CNS HealthcareMemphisTennessee38119-
University of Texas Southwestern Medical CenterDallasTexas75390-9302-
JCCT- Juno NW HoustonHoustonTexas77040-
Consano Clinical Research, LLCShavano ParkTexas78231-
Frontier Clinical Research - KingwoodKingwoodWest Virginia26537-

Find similar trials in Lancaster, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
First Valley Medical Group· Lancaster, CATorrance Clinical Research Institute, Inc.· Lomita, CAArk Clinical Research· Long Beach, CAPacific Clinical Studies· Los Alamitos, CAWetlin Research Associates, Inc.· San Diego, CADiablo Clinical Research, Inc.· Walnut Creek, CA

Related Studies